COPYRIGHT © 2003 by the American College of Chest Physicians.
Cancer II Tuesday, October 28, 2003
4:15 PM - 5:45 PM
|
Pulmonary Blastoma: A Case Report
Todd M. Henderson, MD*,
Octavius Polk, MD and
Michael Brancaccio, MD
Howard University, Silver Spring, MD
INTRODUCTION: Pulmonary blastoma(PB) is a rare primary non-small cell lung cancer(NSCLC) that is composed of both malignant glands and mesenchyme that are primitive/embryonal in appearence. It involves less than 1% of all lung cancers with a frequency about 0.25-0.5%1.
CASE PRESENTATION: This is a case of a 57 year-old female that presented as an outpatient referral for an abnormal chest x-ray(CXR) during pre-operative surgical clearence for knee arthroscopy. She was asymptomatic at presentation with no history of tuberculosis exposure or previous pneumonia. She has a history of asthma/bronchitis requiring bronchodilator therapy and infrequent courses of oral steroids. There was a remote history of smoking tobacco for a year during her teens, otherwise social, occupational, and family history were unremarkable. Physical examination and laboratory values were normal.
CT revealed a 2.2-cm enhancing soft-tissue mass in the apex of the RUL with no evidence of mediastinal or pleural disease present. Pulmonary function testing showed a mild obstructive ventilatory defect with significant reversibility, FEV1 of 1.84- 68% of predicted. A whole body positive emission tomography scan(PET) was negative- no focal area of abnormal radionuclide uptake suggesting a benign process. She had a RUL lobectomy performed for possible curative treatment without any complications. Pathological examination of the specimen was positive for biphasic PB. The surgical margins were clear, and 8 regional lymph nodes were negative for metastasis. The tumor measured 2.8-cm in diameter (well-circumscribed, firm, rubbery mass). Follow-up, currently, involves serial CXRs every 3 months with a chest CT every 12 months depending on the results of the CXRs.
DISCUSSION: PB is a rare NSCLC which morphologically resembles fetal lung structure. It is subdivided into 2 categories: classic biphasic PB and well-differentiated fetal adenocarcinoma2. They may occur at any age, but biphasic PB tends to occur between 35-40 years of age3. There is usually a history of tobacco use with common symptoms of hemoptysis, cough, and fever. 25-40% of cases are asymptomatic, usually an incidental finding4. There maybe pleuritic chest pain associated with pleural effusions5. Radiographic findings are usually a well-demarcated, peripheral lesion favoring upper lobes. It can be large, averaging 10-cm (2.5-25-cm)2 with a rapid growth curve. Biphasic PB has a worse prognosis when compared to fetal adenocarcinoma due to its higher incidence of metastasis with a survival comparable to common NSCLCs. The treatment is similar as well. Surgical resection is the treatment of choice. There are no other therapeutic or adjuvant guidelines which exist6.
CONCLUSION: PET is an accurate, noninvasive means for diagnosis of pulmonary nodules and larger mass lesions7. PB can present as a pulmonary nodule. In this case of PB, it was a false-negative result via PET. The lung cancers that are known in literature to cause a false-negative PET are broncho-alveolar carcinoma and carcinoid tumors.
DISCLOSURE: T.M. Henderson, None.
REFERENCES
- Hasleton P.S, Spencers Pathology of the Lung. 5th Edition 1996McGraw-Hill, New York
- Zaidi et al. PB: Medium-term Results from a Regional Center. Annuals of Thoracic Surgery. 2002;73:15721575
- Zavala-Alarcon et al. Extension of a PB into the Left Atrium. Mayo Clinic Proceedings. 2001;76:657660
- Chin et al. PB in an Adult Presenting as a Chronic Loculated Effusion: a diagnostic problem. Thorax. 1994;49:838839
- Vassilopoulos et al. PB Presenting with Massive Hemothorax. Chest. 1992;102:649650
- Ghaffer et al. PB: A Report of Two Cases. Chest. 1975;67:600602
- Gould et al. Accuracy of PET for Diagnosis of Pulmonary Nodules and Mass Lesions. JAMA. 2001;285(7):914924
Copyright © 2003 by the American College of Chest Physicians.